13P First-line subcutaneous amivantamab plus lazertinib in EGFR-mutated advanced NSCLC: Updated results from the PALOMA-2 study

N. Girard; M. Nagasaka; J. Dias; J.L. Tan; P-J. Voon; C.H. Andrade Teixeira; Kai Tang; S.C. Scott; E. Felip; B. Massuti Sureda; Louise Medley; A. Rittmeyer; S. Das; J. Xie; Ali Alhadab; M. Wang; J. Zhang; S. Shah; S.M. Lim

doi:10.1016/j.esmoop.2026.106320

Key Points

To evaluate the effectiveness and safety of YL202/BNT326 in advanced NSCLC patients with EGFR mutations.
Evaluated YL202/BNT326 in 2L+ non-squamous and squamous NSCLC patients.
Reported safety outcomes including neutropenia and interstitial lung disease (ILD).
Assessed potential combination with pumitamig, an investigational antibody.
YL202/BNT326 demonstrated encouraging efficacy in treated patients.
Reported low rates of neutropenia and ILD, indicating manageable safety profile.
Confirmatory activity observed in EGFR-mutated patient subgroup.

Implication

Clinical trial reveals efficacy of YL202/BNT326 in EGFR-mutated NSCLC, suggesting potential for new treatments.

Abstract

Conclusions:The HER3 ADC YL202/BNT326 shows encouraging efficacy with a manageable safety profile (low neutropenia and ILD rates) in 2L+ non-sq/squamous NSCLC pts without AGA and confirms activity in EGFR-mutated pts.Based on these results, YL202/BNT326 is being evaluated in combination with pumitamig (BNT327), an investigational anti-PD-L1xVEGF-A bispecific antibody, in NSCLC (NCT07111520).Clinical trial identification: NCT06107686.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Girard et al. (2026) studied this question.

synapsesocial.com/papers/69be34f26e48c4981c673096 https://doi.org/10.1016/j.esmoop.2026.106320

View Full Paper

Ask AI

Bookmark

Share

13P First-line subcutaneous amivantamab plus lazertinib in EGFR-mutated advanced NSCLC: Updated results from the PALOMA-2 study

Key Points

Implication

Abstract

Discussion

Cite This Study

13P First-line subcutaneous amivantamab plus lazertinib in EGFR-mutated advanced NSCLC: Updated results from the PALOMA-2 study

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from ESMO Open

Keep reading

More related papers

More from ESMO Open